Aurinia Pharmaceuticals’ voclosporin ophthalmic solution demonstrated positive results in an exploratory phase 2 study evaluating the efficacy, safety and tolerability of the treatment for dry eye syndrome, according to a company press release.
The 100-patient, double-masked study compared voclosporin ophthalmic solution 0.2% and Restasis (cyclosporine ophthalmic emulsion 0.05%, Allergan) twice daily in both eyes for 28 days.
The primary endpoint of drop discomfort at 1 minute on day 1 was not statistically significantly different between the two drugs. However, at 4 weeks, the study drug
Uncategorized